ADC Therapeutics Cuts Price In Second IPO Attempt



  • ADC Therapeutics has filed revised terms for a $125 million U.S. IPO.
  • The firm is developing drug treatment candidates for blood cancers and solid tumors.
  • With a markedly lower price and very strong investor support, the IPO may be worth considering for patient life science investors.
  • Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »

Quick Take

ADC Therapeutics (NYSE:ADCT) intends to raise $125 million from the sale of its common stock, per an amended registration statement.

The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors.

ADCT is making a new attempt to go public at a reasonable valuation and with strong existing investor interest in supporting the IPO.

Company & Technology

Epalinges, Switzerland-based ADC was founded as a spin-off of Spirogen to develop antibody drug conjugates (ADCs - hence the company's name) for the treatment of hematological and solid tumor cancer conditions.

Management is headed by CEO Christopher Martin, who has been with the firm since its formation and was previously CEO of Spirogen, which was acquired by AstraZeneca (AZN) in 2013.

Below is a brief overview video of antibody drug conjugates:

Source: ADC Review

The firm's lead candidates are Lonca and Cami. Lonca has shown strong overall response rates for the treatment of refractory diffuse large B-cell lymphoma.

Cami, which it is developing in collaboration with Genmab A/S, has also shown a high overall response rate for the treatment of relapsed or refractory Hodgkin lymphoma.

Below is the current status of the company’s drug development pipeline:

Source: S-1

Investors in the firm have invested at least $550 million and include Auven Therapeutics, AstraZeneca (AZN) and HPWH TH AG.

Market & Competition

According to a 2017 market research report by Grand View Research, the market for blood cancer treatments was $35.6 billion in 2016.

This represents a forecast CAGR (Compound Annual Growth Rate) of 10.48% from 2018 to 2025.

Key elements driving this expected growth are an increasing number of elderly persons who account for a higher incidence of blood cancer conditions.Below is a chart showing the historical and expected future growth of blood cancer

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis. Get started with a free trial!

This article was written by

Donovan Jones profile picture
Author of IPO Edge
Get IPO Edge with actionable research on next-generation high growth stocks

I'm the founder of IPO Edge on Seeking Alpha, a research service for investors interested in IPOs on US markets. Subscribers receive access to my proprietary research, valuation, data, commentary, opinions, and chat on U.S. IPOs. Join now to get an insider's 'edge' on new issues coming to market, both before and after the IPO. Start with a 14-day Free Trial.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.